PET–CT with (68 Ga)Gallium-Labeled PSMA Ligand for the Diagnosis of Prostate Cancer: Clinical Applications and Protocols
| Autor: | Pricila Gama da Cunha, Daian de Bona Pessoa, Anna Carolina Borges, Felipe Roth Vargas, Letícia Rigo |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Biochemical recurrence
PET-CT medicine.medical_specialty medicine.diagnostic_test business.industry Bone metastasis Context (language use) urologic and male genital diseases medicine.disease Primary tumor 030218 nuclear medicine & medical imaging Metastasis 03 medical and health sciences Prostate cancer 0302 clinical medicine Positron emission tomography 030220 oncology & carcinogenesis medicine Radiology Nuclear Medicine and imaging Radiology business |
| Zdroj: | Current Radiology Reports. 4 |
| ISSN: | 2167-4825 |
| Popis: | The detection of lesions in the context of biochemical recurrence of prostate cancer is a major challenge for all imaging modalities. Recently, the prostate-specific membrane antigen (PSMA) is recognized as a novel target for the PET–CT (positron emission tomography–computed tomography) imaging of prostate cancer with the tracer 68Ga-PSMA (68Gallium-labelled PSMA), mainly in the detection of relapses and metastasis. PSMA PET–CT imaging shows high tracer uptake at the sites of primary tumor and lymph node, and bone metastasis in direct correlation with aggressiveness and Gleason scores. PSMA PET–CT seems to be a highly accurate imaging tool for restaging of prostate cancer patients with biochemical recurrence, and it proved to be clearly superior in detecting prostate cancer lesions at low PSA levels when compared to other methods. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink